SCHEMBL21055602

SCHEMBL21055602

Fc1ccccc1OC1CCC2(CC1)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.47
HTR1A P08908 7/20 0.47
SLC6A3 Q01959 4/20 0.47
SLC6A4 P31645 1/20 0.37
LPAR1 Q92633 1/20 0.37
LPAR5 Q9H1C0 1/20 0.37
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
CACNB4 O00305 1/20 0.36
CACNA1A O00555 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNG3 O60359 1/20 0.36
CACNA1F O60840 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNB3 P54284 1/20 0.36
CACNA2D1 P54289 1/20 0.36
CACNG7 P62955 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNA1D Q01668 1/20 0.36
CACNB1 Q02641 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29966 0.79 SLC6A2 (0.61) SLC6A2HTR1ASLC6A3SLC6A4LPAR1
SCHEMBL12181083 0.78 SLC6A2 (0.53) SLC6A2HTR1ASLC6A3SLC6A4LPAR1
SCHEMBL5527733 0.78 KDM4E (0.42) HTR2CKDM4E
SCHEMBL148028 0.77 HRH1 (0.50) SLC6A2SLC6A3SLC6A4CACNB4CACNA1A
SCHEMBL2369717 0.77 NPC1 (0.36) HTR1ACACNB4CACNA1ACACNA1GCACNG3
SCHEMBL17123797 0.76 SLC6A2 (0.57) SLC6A2HTR1ASLC6A3SLC6A4LPAR1
SCHEMBL5525469 0.76 KDM4E (0.46) KDM4EIDO1
SCHEMBL5521291 0.75 CARM1 (0.48) SLC6A2HTR1ASLC6A3SLC6A4CACNB4
SCHEMBL9538522 0.74 SLC6A2 (0.56) SLC6A2HTR1ASLC6A3SLC6A4LPAR1
SCHEMBL16919126 0.74 MKNK2 (0.35) CACNB4CACNA1ACACNA1GCACNG3CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 SLC6A2 3958/4885HTR1A 2149/4885SLC6A3 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.